Performance analysis of Madrigal Pharmaceuticals (MDGL)
Annual Return
Over the past 3 years, MDGL has had an average annual return of +23.40%, outperforming the benchmark SPY, which returned +22.45% annual.
Over the past 5 years, MDGL has had an average annual return of +37.09%, outperforming the benchmark SPY, which returned +13.88% annual.
Over the past 10 years, MDGL has had an average annual return of +43.77%, outperforming the benchmark SPY, which returned +15.44% annual.
Since Feb 6, 2007, MDGL has had an average annual return of +2.24%, underperforming the benchmark SPY, which returned +10.93% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.18% | +88.72% | +33.36% | -20.28% | +242.45% | -23.76% | +22% | -19.16% | +22.81% | +516.45% | +20.93% | -86.72% |
| 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | ||||
| -49.44% | -41.90% | +93.13% | -23.69% | +20.94% | -17.32% | -8.66% | -26.29% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.97% | -11.71% | +21.17% | -1.17% | -3.89% | -1.84% | -16.18% | ||||||
| 2025 | +8.50% | +1.94% | -2.95% | +0.81% | -17.56% | +9.94% | -0.04% | +44.74% | +4.75% | -8.66% | +42.51% | -2.45% | +88.72% |
| 2024 | -6.34% | +8.98% | +13.07% | -23.60% | +15.75% | +18.63% | +1.60% | -13.18% | -14.13% | +22.22% | +26.55% | -5.98% | +33.36% |
| 2023 | -0.69% | -5.98% | -10.60% | +28.79% | -10.77% | -17.03% | -11.13% | -12.32% | -18.88% | -10.04% | +54.76% | +13.82% | -20.28% |
| 2022 | -32.06% | +61.22% | +5.69% | -28.66% | -5.14% | +7.81% | -12.22% | +14.78% | -9.88% | +8.96% | -0.99% | +313.93% | +242.45% |
| 2021 | +6.84% | +2.04% | -3.47% | +16.34% | -17.48% | -13.26% | -10.35% | -5.25% | -3.58% | -2.55% | +6.38% | +2.46% | -23.76% |
| 2020 | -8.90% | +3.79% | -22.53% | +25.36% | +38.67% | -2.39% | -9.41% | +4.96% | +10.25% | +7.18% | -8.23% | -4.82% | +22% |
| 2019 | +2.71% | +13.38% | -4.58% | -15.32% | -12.90% | +13.43% | -16.70% | +6.20% | -7.00% | +7.20% | +19.76% | -17.68% | -19.16% |
| 2018 | +61.70% | -15.07% | -7.34% | -3.11% | +134.72% | +5.29% | -8.10% | -6.93% | -10.49% | -10.86% | -39.41% | -2.53% | +22.81% |
| 2017 | +2.56% | +2.08% | -1.22% | +7.23% | -7.90% | +6.90% | -4.70% | +10.27% | +163.31% | +11.10% | +0.70% | +82.36% | +516.45% |
Drawdown analysis of Madrigal Pharmaceuticals (MDGL)
The maximum drawdown for the MDGL was -98.40%, occurring on Feb 11, 2016. Recovery took 2396 trading sessions.
The current MDGL drawdown is -19.03%.
Since Feb 6, 2007 MDGL has experienced the following drawdowns:
- 50% or more: 3 times
- 40% or more: 3 times
- 30% or more: 3 times
- 20% or more: 4 times
- 10% or more: 6 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.40% | Jan 28, 2013 | 766 | Feb 11, 2016 | 2396 | Aug 22, 2025 | 3162 |
| -87.64% | Oct 5, 2007 | 351 | Feb 27, 2009 | 981 | Jan 22, 2013 | 1332 |
| -51.42% | Jun 4, 2007 | 58 | Aug 24, 2007 | 28 | Oct 4, 2007 | 86 |
| -29.36% | Dec 22, 2025 | 47 | Mar 3, 2026 | Ongoing | Ongoing | Ongoing |
| -18.88% | Feb 9, 2007 | 40 | Apr 10, 2007 | 38 | Jun 4, 2007 | 78 |
| -10.09% | Sep 30, 2025 | 24 | Nov 3, 2025 | 2 | Nov 5, 2025 | 26 |
| -9.42% | Nov 26, 2025 | 15 | Dec 18, 2025 | 2 | Dec 22, 2025 | 17 |
| -8.01% | Sep 8, 2025 | 7 | Sep 17, 2025 | 9 | Sep 30, 2025 | 16 |
| -4.91% | Nov 11, 2025 | 2 | Nov 13, 2025 | 2 | Nov 17, 2025 | 4 |
| -4.32% | Jan 23, 2013 | 1 | Jan 24, 2013 | 1 | Jan 25, 2013 | 2 |
| -3.02% | Nov 18, 2025 | 2 | Nov 20, 2025 | 2 | Nov 24, 2025 | 4 |
| -1.51% | Aug 29, 2025 | 3 | Sep 4, 2025 | 2 | Sep 8, 2025 | 5 |
| -0.59% | Aug 22, 2025 | 1 | Aug 25, 2025 | 1 | Aug 26, 2025 | 2 |